TAK1 Is Required for Survival of Mouse Fibroblasts Treated with TRAIL, and Does So by NF-κB Dependent Induction of cFLIPL
Josep Maria Lluis, Ulrich Nachbur, Wendy Diane Cook et al. · 2010
Read TAK1 Is Required for Survival of Mouse Fibroblasts Treated with TRAIL, and Does So by NF-κB Dependent Induction of cFLIPL by Josep Maria Lluis, Ulrich Nachbur, Wendy Diane Cook et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0008620.txt.
Description
Josep Maria Lluis and co-authors study cell survival signaling in a 2010 PLOS ONE paper. TRAIL is known as a death ligand in the TNF superfamily. It binds receptors bearing death domains and can kill tumor cells. It can also activate NF-kappaB, a survival pathway. The team study mouse fibroblasts treated with TRAIL. They ask if a kinase called TAK1 is required for their survival. TAK1 sits upstream of NF-kappaB activation.
They find TAK1 is required for survival of fibroblasts treated with TRAIL. It acts by NF-kappaB dependent induction of cFLIPL, a death blocker. Removing TAK1 tips TRAIL from survival signaling toward death. That balance matters for TRAIL-based cancer therapies under development.
Catalog record
| CREATOR | Josep Maria Lluis, Ulrich Nachbur, Wendy Diane Cook et al. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0008620